

**Kratom Revisions**

2026 GENERAL SESSION

STATE OF UTAH

**Chief Sponsor: Evan J. Vickers**

House Sponsor: Jake Sawyer

---

**LONG TITLE****Committee Note:**

The Business and Labor Interim Committee recommended this bill.

Legislative Vote: 16 voting for 0 voting against 4 absent

**General Description:**

This bill amends provisions related to kratom.

**Highlighted Provisions:**

This bill:

- defines terms;
- schedules 7-hydroxymitragynine, including synthetics, if the 7-hydroxymitragynine concentration exceeds a certain percentage as a schedule I controlled substance; and
- schedules Mitragynine pseudoindoxyl, including synthetics.

**Money Appropriated in this Bill:**

None

**Other Special Clauses:**

This bill provides a special effective date.

**Utah Code Sections Affected:**

AMENDS:

**4-45-104**, as enacted by Laws of Utah 2019, Chapter 329

**58-37-2**, as last amended by Laws of Utah 2025, Chapter 396

**58-37-4**, as last amended by Laws of Utah 2025, Chapter 216

---

*Be it enacted by the Legislature of the state of Utah:*

Section 1. Section **4-45-104** is amended to read:

**4-45-104 . Kratom processor requirements -- Criminal penalty.**

(1) A kratom processor may not prepare, distribute, sell, or offer for sale a kratom product:

- (a) that is mixed or packed with a nonkratom substance that affects the quality or strength of the kratom product to such a degree as to render the kratom product

- 31 injurious to a consumer;
- 32 (b) that contains a poisonous or otherwise deleterious nonkratom ingredient, including a
- 33 controlled substance as defined in Section 58-37-2;
- 34 (c) ~~[containing a level of 7-hydroxymitragynine in the alkaloid fraction that is greater~~
- 35 ~~than 2% of the alkaloid composition of the kratom product]~~ that would be considered
- 36 a controlled substance under Section 58-37-4;
- 37 (d) containing a synthetic alkaloid, including synthetic mitragynine, synthetic
- 38 7-hydroxymitragynine, or any other synthetically derived compound of the kratom
- 39 plant; or
- 40 (e) that does not include a product label on the kratom product packaging that states the
- 41 amount of mitragynine and 7-hydroxymitragynine contained in the packaged kratom
- 42 product.
- 43 (2) A kratom processor who violates Subsection (1) is guilty of a class C misdemeanor for
- 44 each violation.
- 45 (3) A kratom processor does not violate Subsection (1) if the kratom processor shows by a
- 46 preponderance of the evidence that the kratom processor relied in good faith upon the
- 47 representation of a manufacturer, processor, packer, or distributor of food represented to
- 48 be a kratom product.
- 49 (4) A kratom processor may not prepare, distribute, sell, or offer for sale a kratom product
- 50 that is not registered with the department in accordance with this chapter.
- 51 (5) A kratom processor shall register as a food establishment in accordance with Section
- 52 4-5-301.

53 Section 2. Section **58-37-2** is amended to read:

54 **58-37-2 . Definitions.**

- 55 (1) As used in this chapter:
- 56 (a) "Administer" means the direct application of a controlled substance, whether by
- 57 injection, inhalation, ingestion, or any other means, to the body of a patient or
- 58 research subject by:
- 59 (i) a practitioner or, in the practitioner's presence, by the practitioner's authorized
- 60 agent; or
- 61 (ii) the patient or research subject at the direction and in the presence of the
- 62 practitioner.
- 63 (b) "Agent" means an authorized person who acts on behalf of or at the direction of a
- 64 manufacturer, distributor, or practitioner but does not include a motor carrier, public

warehouseman, or employee of any of them.

- (c) "Consumption" means ingesting or having any measurable amount of a controlled substance in a person's body, but this Subsection (1)(c) does not include the metabolite of a controlled substance.
- (d) "Continuing criminal enterprise" means any individual, sole proprietorship, partnership, corporation, business trust, association, or other legal entity, and any union or groups of individuals associated in fact although not a legal entity, and includes illicit as well as licit entities created or maintained for the purpose of engaging in conduct which constitutes the commission of episodes of activity made unlawful by this chapter, Chapter 37a, Utah Drug Paraphernalia Act, Chapter 37b, Imitation Controlled Substances Act, Chapter 37c, Utah Controlled Substance Precursor Act, or Chapter 37d, Clandestine Drug Lab Act, which episodes are not isolated, but have the same or similar purposes, results, participants, victims, methods of commission, or otherwise are interrelated by distinguishing characteristics. Taken together, the episodes shall demonstrate continuing unlawful conduct and be related either to each other or to the enterprise.
- (e) "Control" means to add, remove, or change the placement of a drug, substance, or immediate precursor under Section 58-37-3.
- (f)(i) "Controlled substance" means a drug or substance:
- (A) included in Schedules I, II, III, IV, or V of Section 58-37-4;
  - (B) included in Schedules I, II, III, IV, or V of the federal Controlled Substances Act, Title II, P.L. 91-513;
  - (C) that is a controlled substance analog; or
  - (D) listed in Section 58-37-4.2.
- (ii) "Controlled substance" does not include:
- (A) distilled spirits, wine, or malt beverages, as those terms are defined in Title 32B, Alcoholic Beverage Control Act;
  - (B) any drug intended for lawful use in the diagnosis, cure, mitigation, treatment, or prevention of disease in human or other animals, which contains ephedrine, pseudoephedrine, norpseudoephedrine, or phenylpropanolamine if the drug is lawfully purchased, sold, transferred, or furnished as an over-the-counter medication without prescription; or
  - (C) dietary supplements, vitamins, minerals, herbs, or other similar substances including concentrates or extracts, which:

- 99 (I) are not otherwise regulated by law; and  
100 (II) may contain naturally occurring amounts of chemical or substances listed  
101 in this chapter, or in rules adopted pursuant to Title 63G, Chapter 3, Utah  
102 Administrative Rulemaking Act.

103 (g)(i) "Controlled substance analog" means:

- 104 (A) a substance the chemical structure of which is substantially similar to the  
105 chemical structure of a controlled substance listed in Schedules I and II of  
106 Section 58-37-4, a substance listed in Section 58-37-4.2, or in Schedules I and  
107 II of the federal Controlled Substances Act, Title II, P.L. 91-513;  
108 (B) a substance that has a stimulant, depressant, or hallucinogenic effect on the  
109 central nervous system substantially similar to the stimulant, depressant, or  
110 hallucinogenic effect on the central nervous system of controlled substances  
111 listed in Schedules I and II of Section 58-37-4, substances listed in Section  
112 58-37-4.2, or substances listed in Schedules I and II of the federal Controlled  
113 Substances Act, Title II, P.L. 91-513; or  
114 (C) A substance that, with respect to a particular individual, is represented or  
115 intended to have a stimulant, depressant, or hallucinogenic effect on the central  
116 nervous system substantially similar to the stimulant, depressant, or  
117 hallucinogenic effect on the central nervous system of controlled substances  
118 listed in Schedules I and II of Section 58-37-4, substances listed in Section  
119 58-37-4.2, or substances listed in Schedules I and II of the federal Controlled  
120 Substances Act, Title II, P.L. 91-513.

121 (ii) "Controlled substance analog" does not include:

- 122 (A) a controlled substance currently scheduled in Schedules I through V of  
123 Section 58-37-4;  
124 (B) a substance for which there is an approved new drug application;  
125 (C) a substance with respect to which an exemption is in effect for investigational  
126 use by a particular person under Section 505 of the Food, Drug, and Cosmetic  
127 Act, 21 U.S.C. 355, to the extent the conduct with respect to the substance is  
128 permitted by the exemption;  
129 (D) any substance to the extent not intended for human consumption before an  
130 exemption takes effect with respect to the substance;  
131 (E) any drug intended for lawful use in the diagnosis, cure, mitigation, treatment,  
132 or prevention of disease in man or other animals, which contains ephedrine,

- pseudoephedrine, norpseudoephedrine, or phenylpropanolamine if the drug is lawfully purchased, sold, transferred, or furnished as an over-the-counter medication without prescription; or
- (F) dietary supplements, vitamins, minerals, herbs, or other similar substances including concentrates or extracts, which are not otherwise regulated by law, which may contain naturally occurring amounts of chemical or substances listed in this chapter, or in rules adopted pursuant to Title 63G, Chapter 3, Utah Administrative Rulemaking Act.
- (h)(i) "Conviction" means a determination of guilt by verdict, whether jury or bench, or plea, whether guilty or no contest, for any offense proscribed by:
- (A) this chapter;
  - (B) Chapter 37a, Utah Drug Paraphernalia Act;
  - (C) Chapter 37b, Imitation Controlled Substances Act;
  - (D) Chapter 37c, Utah Controlled Substance Precursor Act; or
  - (E) Chapter 37d, Clandestine Drug Lab Act; or
- (ii) for any offense under the laws of the United States and any other state which, if committed in this state, would be an offense under:
- (A) this chapter;
  - (B) Chapter 37a, Utah Drug Paraphernalia Act;
  - (C) Chapter 37b, Imitation Controlled Substances Act;
  - (D) Chapter 37c, Utah Controlled Substance Precursor Act; or
  - (E) Chapter 37d, Clandestine Drug Lab Act.
- (i) "Counterfeit substance" means:
- (i) any controlled substance or container or labeling of any controlled substance that:
    - (A) without authorization bears the trademark, trade name, or other identifying mark, imprint, number, device, or any likeness of them, of a manufacturer, distributor, or dispenser other than the person or persons who in fact manufactured, distributed, or dispensed the substance which falsely purports to be a controlled substance distributed by any other manufacturer, distributor, or dispenser; and
    - (B) a reasonable person would believe to be a controlled substance distributed by an authorized manufacturer, distributor, or dispenser based on the appearance of the substance as described under Subsection (1)(i)(i)(A) or the appearance of the container of that controlled substance; or

- 167 (ii) any substance other than under Subsection (1)(i)(i) that:
- 168 (A) is falsely represented to be any legally or illegally manufactured controlled
- 169 substance; and
- 170 (B) a reasonable person would believe to be a legal or illegal controlled substance.
- 171 (j) "Deliver" or "delivery" means the actual, constructive, or attempted transfer of a
- 172 controlled substance or a listed chemical, whether or not an agency relationship exists.
- 173 (k) "Department" means the Department of Commerce.
- 174 (l) "Depressant or stimulant substance" means:
- 175 (i) a drug which contains any quantity of barbituric acid or any of the salts of
- 176 barbituric acid;
- 177 (ii) a drug which contains any quantity of:
- 178 (A) amphetamine or any of its optical isomers;
- 179 (B) any salt of amphetamine or any salt of an optical isomer of amphetamine; or
- 180 (C) any substance which the Secretary of Health and Human Services or the
- 181 Attorney General of the United States after investigation has found and by
- 182 regulation designated habit-forming because of its stimulant effect on the
- 183 central nervous system;
- 184 (iii) lysergic acid diethylamide; or
- 185 (iv) any drug which contains any quantity of a substance which the Secretary of
- 186 Health and Human Services or the Attorney General of the United States after
- 187 investigation has found to have, and by regulation designated as having, a
- 188 potential for abuse because of its depressant or stimulant effect on the central
- 189 nervous system or its hallucinogenic effect.
- 190 (m) "Dispense" means the delivery of a controlled substance by a pharmacist to an
- 191 ultimate user pursuant to the lawful order or prescription of a practitioner, and
- 192 includes distributing to, leaving with, giving away, or disposing of that substance as
- 193 well as the packaging, labeling, or compounding necessary to prepare the substance
- 194 for delivery.
- 195 (n) "Dispenser" means a pharmacist who dispenses a controlled substance.
- 196 (o) "Distribute" means to deliver other than by administering or dispensing a controlled
- 197 substance or a listed chemical.
- 198 (p) "Distributor" means a person who distributes controlled substances.
- 199 (q) "Division" means the Division of Professional Licensing created in Section 58-1-103.
- 200 (r)(i) "Drug" means:

- 201 (A) a substance recognized in the official United States Pharmacopoeia, Official  
202 Homeopathic Pharmacopoeia of the United States, or Official National  
203 Formulary, or any supplement to any of them, intended for use in the  
204 diagnosis, cure, mitigation, treatment, or prevention of disease in humans or  
205 animals;
- 206 (B) a substance that is required by any applicable federal or state law or rule to be  
207 dispensed by prescription only or is restricted to administration by practitioners  
208 only;
- 209 (C) a substance other than food intended to affect the structure or any function of  
210 the body of humans or other animals; and
- 211 (D) substances intended for use as a component of any substance specified in  
212 Subsections (1)(r)(i)(A), (B), and (C).
- 213 (ii) "Drug" does not include dietary supplements.
- 214 (iii) "Drug" includes a food intended for human consumption that intentionally  
215 contains a vaccine or vaccine material as provided in Section 4-5-107.
- 216 (s) "Drug dependent person" means any individual who unlawfully and habitually uses  
217 any controlled substance to endanger the public morals, health, safety, or welfare, or  
218 who is so dependent upon the use of controlled substances as to have lost the power  
219 of self-control with reference to the individual's dependency.
- 220 (t)(i) "Food" means:
- 221 (A) any nutrient or substance of plant, mineral, or animal origin other than a drug  
222 as specified in this chapter, and normally ingested by human beings; and
- 223 (B) foods for special dietary uses as exist by reason of a physical, physiological,  
224 pathological, or other condition including the conditions of disease,  
225 convalescence, pregnancy, lactation, allergy, hypersensitivity to food,  
226 underweight, and overweight; uses for supplying a particular dietary need  
227 which exist by reason of age including the ages of infancy and childbirth, and  
228 also uses for supplementing and for fortifying the ordinary or unusual diet with  
229 any vitamin, mineral, or other dietary property for use of a food.
- 230 (ii) Any particular use of a food is a special dietary use regardless of the nutritional  
231 purposes.
- 232 (u) "Immediate precursor" means a substance which the Attorney General of the United  
233 States has found to be, and by regulation designated as being, the principal compound  
234 used or produced primarily for use in the manufacture of a controlled substance, or

which is an immediate chemical intermediary used or likely to be used in the manufacture of a controlled substance, the control of which is necessary to prevent, curtail, or limit the manufacture of the controlled substance.

(v) "Indian" means a member of an Indian tribe.

(w) "Indian religion" means a religion:

(i) the origin and interpretation of which is from within a traditional Indian culture or community; and

(ii) that is practiced by Indians.

(x) "Indian tribe" means any tribe, band, nation, pueblo, or other organized group or community of Indians, including any Alaska Native village, which is legally recognized as eligible for and is consistent with the special programs, services, and entitlements provided by the United States to Indians because of their status as Indians.

(y) "Manufacture" means the production, preparation, propagation, compounding, or processing of a controlled substance, either directly or indirectly by extraction from substances of natural origin, or independently by means of chemical synthesis or by a combination of extraction and chemical synthesis.

(z) "Manufacturer" includes any person who packages, repackages, or labels any container of any controlled substance, except pharmacists who dispense or compound prescription orders for delivery to the ultimate consumer.

(aa)(i) "Marijuana" means all species of the genus cannabis and all parts of the genus, whether growing or not, including:

(A) seeds;

(B) resin extracted from any part of the plant, including the resin extracted from the mature stalks;

(C) every compound, manufacture, salt, derivative, mixture, or preparation of the plant, seeds, or resin;

(D) any synthetic equivalents of the substances contained in the plant cannabis sativa or any other species of the genus cannabis which are chemically indistinguishable and pharmacologically active; and

(E) any component part or cannabinoid extracted or isolated from the plant, including extracted or isolated tetrahydrocannabinols.

(ii) "Marijuana" does not include:

(A) the mature stalks of the plant;



- 269 (B) fiber produced from the stalks;  
270 (C) oil or cake made from the seeds of the plant;  
271 (D) except as provided in Subsection (1)(aa)(i), any other compound,  
272 manufacture, salt, derivative, mixture, or preparation of the mature stalks,  
273 fiber, oil or cake;  
274 (E) the sterilized seed of the plant which is incapable of germination;  
275 (F) any compound, mixture, or preparation approved by the federal Food and  
276 Drug Administration under the federal Food, Drug, and Cosmetic Act, 21  
277 U.S.C. Sec. 301 et seq. that is not listed in a schedule of controlled substances  
278 in Section 58-37-4 or in the federal Controlled Substances Act, Title II, P.L.  
279 91-513; or  
280 (G) transportable industrial hemp concentrate as that term is defined in Section  
281 4-41-102.
- 282 (bb) "Money" means officially issued coin and currency of the United States or any  
283 foreign country.
- 284 (cc) "Narcotic drug" means any of the following, whether produced directly or indirectly  
285 by extraction from substances of vegetable origin, or independently by means of  
286 chemical synthesis, or by a combination of extraction and chemical synthesis:  
287 (i) opium, coca leaves, and opiates;  
288 (ii) a compound, manufacture, salt, derivative, or preparation of opium, coca leaves,  
289 or opiates;  
290 (iii) opium poppy and poppy straw; or  
291 (iv) a substance, and any compound, manufacture, salt, derivative, or preparation of  
292 the substance, which is chemically identical with any of the substances referred to  
293 in Subsection (1)(cc)(i), (ii), or (iii), except narcotic drug does not include  
294 decocainized coca leaves or extracts of coca leaves which do not contain cocaine  
295 or ecgonine.
- 296 (dd) "Negotiable instrument" means documents, containing an unconditional promise to  
297 pay a sum of money, which are legally transferable to another party by endorsement  
298 or delivery.
- 299 (ee) "Opiate" means any drug or other substance having an addiction-forming or  
300 addiction-sustaining liability similar to morphine or being capable of conversion into  
301 a drug having addiction-forming or addiction-sustaining liability.
- 302 (ff) "Opium poppy" means the plant of the species *papaver somniferum* L., except the

seeds of the plant.

(gg) "Person" means any corporation, association, partnership, trust, other institution or entity or one or more individuals.

(hh) "Poppy straw" means all parts, except the seeds, of the opium poppy, after mowing.

(ii) "Possession" or "use" means the joint or individual ownership, control, occupancy, holding, retaining, belonging, maintaining, or the application, inhalation, swallowing, injection, or consumption, as distinguished from distribution, of controlled substances and includes individual, joint, or group possession or use of controlled substances. For a person to be a possessor or user of a controlled substance, it is not required that the person be shown to have individually possessed, used, or controlled the substance, but it is sufficient if it is shown that the person jointly participated with one or more persons in the use, possession, or control of any substances with knowledge that the activity was occurring, or the controlled substance is found in a place or under circumstances indicating that the person had the ability and the intent to exercise dominion and control over the controlled substance.

(jj) "Practitioner" means a physician, dentist, naturopathic physician, veterinarian, pharmacist, scientific investigator, pharmacy, hospital, or other person licensed, registered, or otherwise permitted to distribute, dispense, conduct research with respect to, administer, or use in teaching or chemical analysis a controlled substance in the course of professional practice or research in this state.

(kk) "Prescribe" means to issue a prescription:

(i) orally or in writing; or

(ii) by telephone, facsimile transmission, computer, or other electronic means of communication as defined by division rule.

(ll) "Prescription" means an order issued:

(i) by a licensed practitioner, in the course of that practitioner's professional practice or by collaborative pharmacy practice agreement; and

(ii) for a controlled substance or other prescription drug or device for use by a patient or an animal.

(mm) "Production" means the manufacture, planting, cultivation, growing, or harvesting of a controlled substance.

(nn) "Securities" means any stocks, bonds, notes, or other evidences of debt or of property.

(oo) "State" means the state of Utah.

(pp) "Total kratom alkaloid composition" means the total amount of all alkaloids derived from the *Mitragyna speciosa* plant.

~~(pp)~~ (qq) "Ultimate user" means any person who lawfully possesses a controlled substance for the person's own use, for the use of a member of the person's household, or for administration to an animal owned by the person or a member of the person's household.

(2) If a term used in this chapter is not defined, the definition and terms of Title 76, Utah Criminal Code, shall apply.

Section 3. Section **58-37-4** is amended to read:

**58-37-4 . Schedules of controlled substances -- Schedules I through V -- Findings required -- Specific substances included in schedules.**

(1) There are established five schedules of controlled substances known as Schedules I, II, III, IV, and V which consist of substances listed in this section.

(2) Schedules I, II, III, IV, and V consist of the following drugs or other substances by the official name, common or usual name, chemical name, or brand name designated:

(a) Schedule I:

(i) Unless specifically excepted or unless listed in another schedule, any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, when the existence of the isomers, esters, ethers, and salts is possible within the specific chemical designation:

(A) Acetyl-alpha-methylfentanyl

(N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N-phenylacetamide);

(B) Acetyl fentanyl: (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide);

(C) Acetylmethadol;

(D) Acryl fentanyl (N-(1-Phenethylpiperidin-4-yl)-N-phenylacrylamide);

(E) Allylprodine;

(F) Alphacetylmethadol, except levo-alphacetylmethadol also known as levo-alpha-acetylmethadol, levomethadyl acetate, or LAAM;

(G) Alphameprodine;

(H) Alphamethadol;

(I) Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-phenyl)ethyl-4-piperidyl] propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-propanilido) piperidine);

(J) Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide);

371 (K) Benzylpiperazine;  
372 (L) Benzethidine;  
373 (M) Betacetylmethadol;  
374 (N) Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-  
375 piperidiny]-N-phenylpropanamide);  
376 (O) Beta-hydroxy-3-methylfentanyl, other name: N-[1-(2-hydroxy-2-  
377 phenethyl)-3-methyl-4-piperidiny]-N-phenylpropanamide;  
378 (P) Betameprodine;  
379 (Q) Betamethadol;  
380 (R) Betaprodine;  
381 (S) Butyryl fentanyl (N-(1-(2-phenylethyl)-4-piperidiny)-N-phenylbutyramide);  
382 (T) Clonitazene;  
383 (U) Cyclopropyl fentanyl  
384 (N-(1-Phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide);  
385 (V) Dextromoramide;  
386 (W) Diampromide;  
387 (X) Diethylthiambutene;  
388 (Y) Difenoxin;  
389 (Z) Dimenoxadol;  
390 (AA) Dimepheptanol;  
391 (BB) Dimethylthiambutene;  
392 (CC) Dioxaphetyl butyrate;  
393 (DD) Dipipanone;  
394 (EE) Ethylmethylthiambutene;  
395 (FF) Etizolam  
396 (1-Methyl-6-o-chlorophenyl-8-ethyl-4H-s-triazolo[3,4-c]thieno[2,3-e]1,4-diazepine);  
397 (GG) Etonitazene;  
398 (HH) Etoxeridine;  
399 (II) Furanyl fentanyl (N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]  
400 furan-2-carboxamide);  
401 (JJ) Furethidine;  
402 (KK) Hydroxypethidine;  
403 (LL) Ketobemidone;  
404 (MM) Levomoramide;

405 (NN) Levophenacylmorphane;  
406 (OO) Methoxyacetyl fentanyl  
407 (2-Methoxy-N-(1-phenylethylpiperidin-4-yl)-N-acetamide);  
408 (PP) Morpheridine;  
409 (QQ) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);  
410 (RR) Noracymethadol;  
411 (SS) Norlevorphanol;  
412 (TT) Normethadone;  
413 (UU) Norpipanone;  
414 (VV) Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-4-piperidinyl]  
415 propanamide);  
416 (WW) Para-fluoroisobutyryl fentanyl  
417 (N-(4-Fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide);  
418 (XX) PEPAP (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine);  
419 (YY) Phenadoxone;  
420 (ZZ) Phenampromide;  
421 (AAA) Phenibut;  
422 (BBB) Phenomorphan;  
423 (CCC) Phenoperidine;  
424 (DDD) Piritramide;  
425 (EEE) Proheptazine;  
426 (FFF) Properidine;  
427 (GGG) Propiram;  
428 (HHH) Racemoramide;  
429 (III) Tetrahydrofuran fentanyl  
430 (N-(1-Phenethylpiperidin-4-yl)-N-phenyltetrahydrofuran-2-carboxamide);  
431 (JJJ) Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]-propanamide;  
432 (KKK) Tianeptine;  
433 (LLL) Tilidine;  
434 (MMM) Trimeperidine;  
435 (NNN) 3-methylfentanyl, including the optical and geometric isomers  
436 (N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]-N-phenylpropanamide);  
437 (OOO) 3-methylthiofentanyl  
438 (N-[(3-methyl-1-(2-thienyl)ethyl-4-piperidinyl)-N-phenylpropanamide);

439 (PPP) 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide also  
440 known as U-47700; and

441 (QQQ) 4-cyano CUMYL-BUTINACA.

442 (ii) Unless specifically excepted or unless listed in another schedule, any of the  
443 following opium derivatives, their salts, isomers, and salts of isomers when the  
444 existence of the salts, isomers, and salts of isomers is possible within the specific  
445 chemical designation:

446 (A) Acetorphine;

447 (B) Acetyldihydrocodeine;

448 (C) Benzylmorphine;

449 (D) Codeine methylbromide;

450 (E) Codeine-N-Oxide;

451 (F) Cyprenorphine;

452 (G) Desomorphine;

453 (H) Dihydromorphine;

454 (I) Drotebanol;

455 (J) Etorphine (except hydrochloride salt);

456 (K) Heroin;

457 (L) Hydromorphenol;

458 (M) Methyldesorphine;

459 (N) Methylhydromorphine;

460 (O) Morphine methylbromide;

461 (P) Morphine methylsulfonate;

462 (Q) Morphine-N-Oxide;

463 (R) Myrophine;

464 (S) Nicocodeine;

465 (T) Nicomorphine;

466 (U) Normorphine;

467 (V) Pholcodine; and

468 (W) Thebacon.

469 (iii) Unless specifically excepted or unless listed in another schedule, any material,  
470 compound, mixture, or preparation which contains any quantity of the following  
471 hallucinogenic substances, or which contains any of their salts, isomers, and salts  
472 of isomers when the existence of the salts, isomers, and salts of isomers is possible

within the specific chemical designation; as used in this Subsection (2)(a)(iii) only, "isomer" includes the optical, position, and geometric isomers:

(A) Alpha-ethyltryptamine, some trade or other names: etryptamine; Monase;  $\alpha$ -ethyl-1H-indole-3-ethanamine; 3-(2-aminobutyl) indole;  $\alpha$ -ET; and AET;

(B) 4-bromo-2,5-dimethoxy-amphetamine, some trade or other names: 4-bromo-2,5-dimethoxy- $\alpha$ -methylphenethylamine; 4-bromo-2,5-DMA;

(C) 4-bromo-2,5-dimethoxyphenethylamine, some trade or other names: 2-(4-bromo-2,5-dimethoxyphenyl)-1-aminoethane; alpha-desmethyl DOB; 2C-B, Nexus;

(D) 2,5-dimethoxyamphetamine, some trade or other names: 2,5-dimethoxy- $\alpha$ -methylphenethylamine; 2,5-DMA;

(E) 2,5-dimethoxy-4-ethylamphetamine, some trade or other names: DOET;

(F) 4-methoxyamphetamine, some trade or other names: 4-methoxy- $\alpha$ -methylphenethylamine; paramethoxyamphetamine, PMA;

(G) 5-methoxy-3,4-methylenedioxyamphetamine;

(H) 4-methyl-2,5-dimethoxy-amphetamine, some trade and other names: 4-methyl-2,5-dimethoxy- $\alpha$ -methylphenethylamine; "DOM"; and "STP";

(I) 3,4-methylenedioxy amphetamine;

(J) 3,4-methylenedioxymethamphetamine (MDMA);

(K) 3,4-methylenedioxy-N-ethylamphetamine, also known as N-ethyl-alpha-methyl-3,4(methylenedioxy)phenethylamine, N-ethyl MDA, MDE, MDEA;

(L) N-hydroxy-3,4-methylenedioxyamphetamine, also known as N-hydroxy-alpha-methyl-3,4(methylenedioxy)phenethylamine, and N-hydroxy MDA;

(M) 3,4,5-trimethoxy amphetamine;

(N) Bufotenine, some trade and other names: 3-( $\beta$ -Dimethylaminoethyl)-5-hydroxyindole; 3-(2-dimethylaminoethyl)-5-indolol; N, N-dimethylserotonin; 5-hydroxy-N,N-dimethyltryptamine; mappine;

(O) Diethyltryptamine, some trade and other names: N,N-Diethyltryptamine; DET;

(P) Dimethyltryptamine, some trade or other names: DMT;

(Q) Ibogaine, some trade and other names: 7-Ethyl-6,6 $\beta$ -7,8,9,10,12,13-octahydro-2-methoxy-6,9-methano-5H-pyrido [1', 2':1,2]

azepino [5,4-b] indole; Tabernanthe iboga;

(R) Lysergic acid diethylamide;

(S) Marijuana;

(T) Mescaline;

(U) Parahexyl, some trade or other names:

3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran;

Synhexyl;

(V) Peyote, meaning all parts of the plant presently classified botanically as

Lophophora williamsii Lemaire, whether growing or not, the seeds thereof, any

extract from any part of such plant, and every compound, manufacture, salts,

derivative, mixture, or preparation of such plant, its seeds or extracts

(Interprets 21 USC 812(c), Schedule I(c) (12));

(W) N-ethyl-3-piperidyl benzilate;

(X) N-methyl-3-piperidyl benzilate;

(Y) Psilocybin;

(Z) Psilocyn;

(AA) Tetrahydrocannabinols, naturally contained in a plant of the genus Cannabis (cannabis plant), except for marijuana as defined in Subsection 58-37-2

(1)(aa)(i)(E), as well as synthetic equivalents of the substances contained in the

cannabis plant, or in the resinous extractives of Cannabis, sp. and/or synthetic

substances, derivatives, and their isomers with similar chemical structure and

pharmacological activity to those substances contained in the plant, such as the

following:  $\Delta^1$  cis or trans tetrahydrocannabinol, and their optical isomers  $\Delta^6$  cis or

trans tetrahydrocannabinol, and their optical isomers  $\Delta^3,4$  cis or trans

tetrahydrocannabinol, and its optical isomers, and since nomenclature of these

substances is not internationally standardized, compounds of these structures,

regardless of numerical designation of atomic positions covered;

(BB) Ethylamine analog of phencyclidine, some trade or other names:

N-ethyl-1-phenylcyclohexylamine, (1-phenylcyclohexyl)ethylamine,

N-(1-phenylcyclohexyl)ethylamine, cyclohexamine, PCE;

(CC) Pyrrolidine analog of phencyclidine, some trade or other names:

1-(1-phenylcyclohexyl)-pyrrolidine, PCPy, PHP;

(DD) Thiophene analog of phencyclidine, some trade or other names:

1-[1-(2-thienyl)-cyclohexyl]-piperidine, 2-thienylanalog of phencyclidine,



- 540 TPCP, TCP; and  
541 (EE) 1-[1-(2-thienyl)cyclohexyl]pyrrolidine, some other names: TCPy.
- 542 (iv) Unless specifically excepted or unless listed in another schedule, any material  
543 compound, mixture, or preparation which contains any quantity of the following  
544 substances having a depressant effect on the central nervous system, including its  
545 salts, isomers, and salts of isomers when the existence of the salts, isomers, and  
546 salts of isomers is possible within the specific chemical designation:
- 547 (A) Mecloqualone; and  
548 (B) Methaqualone.
- 549 (v) Any material, compound, mixture, or preparation containing any quantity of the  
550 following substances having a stimulant effect on the central nervous system,  
551 including their salts, isomers, and salts of isomers:
- 552 (A) Aminorex, some other names: aminoxaphen; 2-amino-5-phenyl-2-oxazoline;  
553 or 4,5-dihydro-5-phenyl-2-oxazamine;  
554 (B) Cathinone, some trade or other names: 2-amino-1-phenyl-1-propanone,  
555 alpha-aminopropiophenone, 2-aminopropiophenone, and norephedrone;  
556 (C) Fenethylamine;  
557 (D) Methcathinone, some other names: 2-(methylamino)-propionophenone;  
558 alpha-(methylamino)propionophenone; 2-(methylamino)-1-phenylpropan-1-one;  
559 alpha-N-methylaminopropionophenone; monomethylpropion; ephedrone;  
560 N-methylcathinone; methylcathinone; AL-464; AL-422; AL-463 and UR1432,  
561 its salts, optical isomers, and salts of optical isomers;  
562 (E) (±)cis-4-methylaminorex ((±)cis-4,5-dihydro-4-methyl-5-phenyl-2-oxazamine);  
563 (F) N-ethylamphetamine; and  
564 (G) N,N-dimethylamphetamine, also known as  
565 N,N-alpha-trimethyl-benzeneethanamine; N,N-alpha-trimethylphenethylamine.
- 566 (vi) Any material, compound, mixture, or preparation which contains any quantity of  
567 the following substances, including their optical isomers, salts, and salts of  
568 isomers, subject to temporary emergency scheduling:
- 569 (A) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide (benzylfentanyl); and  
570 (B) N-[1-(2-thienyl)methyl-4-piperidyl]-N-phenylpropanamide (thenylfentanyl).
- 571 (vii) Unless specifically excepted or unless listed in another schedule, any material,  
572 compound, mixture, or preparation which contains any quantity of gamma  
573 hydroxy butyrate (gamma hydrobutyric acid), including its salts, isomers, and

574 salts of isomers.

575 (viii) Unless specifically excepted or unless listed in another schedule, the following  
576 substances commonly found in *Mitragyna speciosa*, including synthetic versions,  
577 isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, when the  
578 existence of the isomers, esters, ethers, and salts is possible within the specific  
579 chemical designation:

- 580 (A) 7-hydroxymitragynine (methyl  
581 (E)-2[(2S,3S,7aS,12bS)-3-ethyl-7a-hydroxy-8-methoxy-2,3,4,6,7,12b-hexahydro-  
582 1H-indolo[2,3-a]quinolizin-2-yl]-3-methoxyprop-2-enoate), that is  
583 concentrated at a level greater than .4% of the total kratom alkaloid  
584 composition of any substance or product; and
- 585 (B) Mitragynine pseudoindoxyl (methyl  
586 (E)-2-[(2S,6'S,7'S,8'aS)-6'-ethyl-4-methoxy-3-oxospiro[1H-indole-2,1'-3,5,6,7,8,8a-  
587 hexahydro-2H-indolizine]-7'-yl]-3-methoxyprop-2-enoate).

588 (b) Schedule II:

589 (i) Unless specifically excepted or unless listed in another schedule, any of the  
590 following substances whether produced directly or indirectly by extraction from  
591 substances of vegetable origin, or independently by means of chemical synthesis,  
592 or by a combination of extraction and chemical synthesis:

- 593 (A) Opium and opiate, and any salt, compound, derivative, or preparation of  
594 opium or opiate, excluding apomorphine, dextrophan, nalbuphine, nalmeferene,  
595 naloxone, and naltrexone, and their respective salts, but including:
- 596 (I) Raw opium;
  - 597 (II) Opium extracts;
  - 598 (III) Opium fluid;
  - 599 (IV) Powdered opium;
  - 600 (V) Granulated opium;
  - 601 (VI) Tincture of opium;
  - 602 (VII) Codeine;
  - 603 (VIII) Ethylmorphine;
  - 604 (IX) Etorphine hydrochloride;
  - 605 (X) Hydrocodone;
  - 606 (XI) Hydromorphone;
  - 607 (XII) Metopon;

- 608 (XIII) Morphine;  
609 (XIV) Oxycodone;  
610 (XV) Oxymorphone; and  
611 (XVI) Thebaine;
- 612 (B) Any salt, compound, derivative, or preparation which is chemically equivalent  
613 or identical with any of the substances referred to in Subsection (2)(b)(i)(A),  
614 except that these substances may not include the isoquinoline alkaloids of  
615 opium;
- 616 (C) Opium poppy and poppy straw;
- 617 (D) Coca leaves and any salt, compound, derivative, or preparation of coca leaves,  
618 and any salt, compound, derivative, or preparation which is chemically  
619 equivalent or identical with any of these substances, and includes cocaine and  
620 ecgonine, their salts, isomers, derivatives, and salts of isomers and derivatives,  
621 whether derived from the coca plant or synthetically produced, except the  
622 substances may not include decocainized coca leaves or extraction of coca  
623 leaves, which extractions do not contain cocaine or ecgonine; and
- 624 (E) Concentrate of poppy straw, which means the crude extract of poppy straw in  
625 either liquid, solid, or powder form which contains the phenanthrene alkaloids  
626 of the opium poppy.
- 627 (ii) Unless specifically excepted or unless listed in another schedule, any of the  
628 following opiates, including their isomers, esters, ethers, salts, and salts of  
629 isomers, esters, and ethers, when the existence of the isomers, esters, ethers, and  
630 salts is possible within the specific chemical designation, except dextrorphan and  
631 levopropoxyphene:
- 632 (A) Alfentanil;  
633 (B) Alphaprodine;  
634 (C) Anileridine;  
635 (D) Bezitramide;  
636 (E) Bulk dextropropoxyphene (nondosage forms);  
637 (F) Carfentanil;  
638 (G) Dihydrocodeine;  
639 (H) Diphenoxylate;  
640 (I) Fentanyl;  
641 (J) Isomethadone;

- 642 (K) Levo-alphaacetylmethadol, some other names: levo-alpha-acetylmethadol,  
643 levomethadyl acetate, or LAAM;
- 644 (L) Levomethorphan;
- 645 (M) Levorphanol;
- 646 (N) Metazocine;
- 647 (O) Methadone;
- 648 (P) Methadone-Intermediate, 4-cyano-2-dimethylamino-4, 4-diphenyl butane;
- 649 (Q) Moramide-Intermediate, 2-methyl-3-morpholino-1,  
650 1-diphenylpropane-carboxylic acid;
- 651 (R) Pethidine (meperidine);
- 652 (S) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine;
- 653 (T) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate;
- 654 (U) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic acid;
- 655 (V) Phenazocine;
- 656 (W) Piminodine;
- 657 (X) Racemethorphan;
- 658 (Y) Racemorphan;
- 659 (Z) Remifentanil; and
- 660 (AA) Sufentanil.
- 661 (iii) Unless specifically excepted or unless listed in another schedule, any material,  
662 compound, mixture, or preparation which contains any quantity of the following  
663 substances having a stimulant effect on the central nervous system:
- 664 (A) Amphetamine, its salts, optical isomers, and salts of its optical isomers;
- 665 (B) Methamphetamine, its salts, isomers, and salts of its isomers;
- 666 (C) Phenmetrazine and its salts; and
- 667 (D) Methylphenidate.
- 668 (iv) Unless specifically excepted or unless listed in another schedule, any material,  
669 compound, mixture, or preparation which contains any quantity of the following  
670 substances having a depressant effect on the central nervous system, including its  
671 salts, isomers, and salts of isomers when the existence of the salts, isomers, and  
672 salts of isomers is possible within the specific chemical designation:
- 673 (A) Amobarbital;
- 674 (B) Glutethimide;
- 675 (C) Pentobarbital;

- 676 (D) Phencyclidine;
- 677 (E) Phencyclidine immediate precursors: 1-phenylcyclohexylamine and
- 678 1-piperidinocyclohexanecarbonitrile (PCC); and
- 679 (F) Secobarbital.
- 680 (v)(A) Unless specifically excepted or unless listed in another schedule, any
- 681 material, compound, mixture, or preparation which contains any quantity of
- 682 Phenylacetone.
- 683 (B) Some of these substances may be known by trade or other names:
- 684 phenyl-2-propanone; P2P; benzyl methyl ketone; and methyl benzyl ketone.
- 685 (vi) Nabilone, another name for nabilone: ( $\pm$
- 686 )-trans-3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-hydroxy-6,
- 687 6-dimethyl-9H-dibenzo[b,d]pyran-9-one.
- 688 (vii) A drug product or preparation that contains any component of marijuana,
- 689 including tetrahydrocannabinol, and is approved by the United States Food and
- 690 Drug Administration and scheduled by the Drug Enforcement Administration in
- 691 Schedule II of the federal Controlled Substances Act, Title II, P.L. 91-513.
- 692 (c) Schedule III:
- 693 (i) Unless specifically excepted or unless listed in another schedule, any material,
- 694 compound, mixture, or preparation which contains any quantity of the following
- 695 substances having a stimulant effect on the central nervous system, including its
- 696 salts, isomers whether optical, position, or geometric, and salts of the isomers
- 697 when the existence of the salts, isomers, and salts of isomers is possible within the
- 698 specific chemical designation:
- 699 (A) Those compounds, mixtures, or preparations in dosage unit form containing
- 700 any stimulant substances listed in Schedule II, which compounds, mixtures, or
- 701 preparations were listed on August 25, 1971, as excepted compounds under
- 702 Section 1308.32 of Title 21 of the Code of Federal Regulations, and any other
- 703 drug of the quantitative composition shown in that list for those drugs or which
- 704 is the same except that it contains a lesser quantity of controlled substances;
- 705 (B) Benzphetamine;
- 706 (C) Chlorphentermine;
- 707 (D) Clortermine; and
- 708 (E) Phendimetrazine.
- 709 (ii) Unless specifically excepted or unless listed in another schedule, any material,

710 compound, mixture, or preparation which contains any quantity of the following  
711 substances having a depressant effect on the central nervous system:

712 (A) Any compound, mixture, or preparation containing amobarbital, secobarbital,  
713 pentobarbital, or any salt of any of them, and one or more other active  
714 medicinal ingredients which are not listed in any schedule;

715 (B) Any suppository dosage form containing amobarbital, secobarbital, or  
716 pentobarbital, or any salt of any of these drugs which is approved by the United  
717 States Food and Drug Administration for marketing only as a suppository;

718 (C) Any substance which contains any quantity of a derivative of barbituric acid  
719 or any salt of any of them;

720 (D) Chlorhexadol;

721 (E) Buprenorphine;

722 (F) Any drug product containing gamma hydroxybutyric acid, including its salts,  
723 isomers, and salts of isomers, for which an application is approved under the  
724 federal Food, Drug, and Cosmetic Act, Section 505;

725 (G) Ketamine, its salts, isomers, and salts of isomers, some other names for  
726 ketamine:  $\pm$  -2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone;

727 (H) Lysergic acid;

728 (I) Lysergic acid amide;

729 (J) Methyprylon;

730 (K) Sulfondiethylmethane;

731 (L) Sulfonethylmethane;

732 (M) Sulfonmethane; and

733 (N) Tiletamine and zolazepam or any of their salts, some trade or other names for  
734 a tiletamine-zolazepam combination product: Telazol, some trade or other  
735 names for tiletamine: 2-(ethylamino)-2-(2-thienyl)-cyclohexanone, some trade  
736 or other names for zolazepam:

737 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-[3,4-e]  
738 [1,4]-diazepin-7(1H)-one, flupyrzapon.

739 (iii) Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in  
740 a U.S. Food and Drug Administration approved drug product, some other names  
741 for dronabinol:

742 (6aR-trans)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol,  
743 or (-)-delta-9-(trans)-tetrahydrocannabinol.

- (iv) Nalorphine.
- (v) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing limited quantities of any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid:
- (A) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opium;
  - (B) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active non-narcotic ingredients in recognized therapeutic amounts;
  - (C) Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more than 15 milligrams per dosage unit, with a fourfold or greater quantity of an isoquinoline alkaloid of opium;
  - (D) Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, non-narcotic ingredients in recognized therapeutic amounts;
  - (E) Not more than 1.8 grams of dihydrocodeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active non-narcotic ingredients in recognized therapeutic amounts;
  - (F) Not more than 300 milligrams of ethylmorphine per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, non-narcotic ingredients in recognized therapeutic amounts;
  - (G) Not more than 500 milligrams of opium per 100 milliliters or per 100 grams, or not more than 25 milligrams per dosage unit, with one or more active, non-narcotic ingredients in recognized therapeutic amounts; and
  - (H) Not more than 50 milligrams of morphine per 100 milliliters or per 100 grams with one or more active, non-narcotic ingredients in recognized therapeutic amounts.
- (vi) Unless specifically excepted or unless listed in another schedule, anabolic steroids including any of the following or any isomer, ester, salt, or derivative of the following that promotes muscle growth:
- (A) Boldenone;
  - (B) Chlorotestosterone (4-chlortestosterone);

- 778 (C) Clostebol;  
779 (D) Dehydrochlormethyltestosterone;  
780 (E) Dihydrotestosterone (4-dihydrotestosterone);  
781 (F) Drostanolone;  
782 (G) Ethylestrenol;  
783 (H) Fluoxymesterone;  
784 (I) Formebolone (formebolone);  
785 (J) Mesterolone;  
786 (K) Methandienone;  
787 (L) Methandranone;  
788 (M) Methandriol;  
789 (N) Methandrostenolone;  
790 (O) Methenolone;  
791 (P) Methyltestosterone;  
792 (Q) Mibolerone;  
793 (R) Nandrolone;  
794 (S) Norethandrolone;  
795 (T) Oxandrolone;  
796 (U) Oxymesterone;  
797 (V) Oxymetholone;  
798 (W) Stanolone;  
799 (X) Stanozolol;  
800 (Y) Testolactone;  
801 (Z) Testosterone; and  
802 (AA) Trenbolone.
- 803 (vii) Anabolic steroids expressly intended for administration through implants to  
804 cattle or other nonhuman species, and approved by the Secretary of Health and  
805 Human Services for use, may not be classified as a controlled substance.
- 806 (viii) A drug product or preparation that contains any component of marijuana,  
807 including tetrahydrocannabinol, and is approved by the United States Food and  
808 Drug Administration and scheduled by the Drug Enforcement Administration in  
809 Schedule III of the federal Controlled Substances Act, Title II, P.L. 91-513.
- 810 (ix) Nabiximols.
- 811 (d) Schedule IV:



- 812 (i) Unless specifically excepted or unless listed in another schedule, any material,  
813 compound, mixture, or preparation containing not more than 1 milligram of  
814 difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit, or  
815 any salts of any of them.
- 816 (ii) Unless specifically excepted or unless listed in another schedule, any material,  
817 compound, mixture, or preparation which contains any quantity of the following  
818 substances, including its salts, isomers, and salts of isomers when the existence of  
819 the salts, isomers, and salts of isomers is possible within the specific chemical  
820 designation:
- 821 (A) Alprazolam;
  - 822 (B) Barbitol;
  - 823 (C) Bromazepam;
  - 824 (D) Butorphanol;
  - 825 (E) Camazepam;
  - 826 (F) Carisoprodol;
  - 827 (G) Chloral betaine;
  - 828 (H) Chloral hydrate;
  - 829 (I) Chlordiazepoxide;
  - 830 (J) Clobazam;
  - 831 (K) Clonazepam;
  - 832 (L) Clorazepate;
  - 833 (M) Clotiazepam;
  - 834 (N) Cloxazolam;
  - 835 (O) Delorazepam;
  - 836 (P) Diazepam;
  - 837 (Q) Dichloralphenazone;
  - 838 (R) Estazolam;
  - 839 (S) Ethchlorvynol;
  - 840 (T) Ethinamate;
  - 841 (U) Ethyl loflazepate;
  - 842 (V) Fludiazepam;
  - 843 (W) Flunitrazepam;
  - 844 (X) Flurazepam;
  - 845 (Y) Halazepam;

- 846 (Z) Haloxazolam;  
847 (AA) Ketazolam;  
848 (BB) Loprazolam;  
849 (CC) Lorazepam;  
850 (DD) Lormetazepam;  
851 (EE) Mebutamate;  
852 (FF) Medazepam;  
853 (GG) Meprobamate;  
854 (HH) Methohexital;  
855 (II) Methylphenobarbital (mephobarbital);  
856 (JJ) Midazolam;  
857 (KK) Nimetazepam;  
858 (LL) Nitrazepam;  
859 (MM) Nordiazepam;  
860 (NN) Oxazepam;  
861 (OO) Oxazolam;  
862 (PP) Paraldehyde;  
863 (QQ) Pentazocine;  
864 (RR) Petrichloral;  
865 (SS) Phenobarbital;  
866 (TT) Pinazepam;  
867 (UU) Prazepam;  
868 (VV) Quazepam;  
869 (WW) Temazepam;  
870 (XX) Tetrazepam;  
871 (YY) Tramadol;  
872 (ZZ) Triazolam;  
873 (AAA) Zaleplon; and  
874 (BBB) Zolpidem.
- 875 (iii) Any material, compound, mixture, or preparation of fenfluramine which contains  
876 any quantity of the following substances, including its salts, isomers whether  
877 optical, position, or geometric, and salts of the isomers when the existence of the  
878 salts, isomers, and salts of isomers is possible.
- 879 (iv) Unless specifically excepted or unless listed in another schedule, any material,

- 880 compound, mixture, or preparation which contains any quantity of the following  
881 substances having a stimulant effect on the central nervous system, including its  
882 salts, isomers whether optical, position, or geometric isomers, and salts of the  
883 isomers when the existence of the salts, isomers, and salts of isomers is possible  
884 within the specific chemical designation:
- 885 (A) Cathine ((+)-norpseudoephedrine);
  - 886 (B) Diethylpropion;
  - 887 (C) Fencamfamine;
  - 888 (D) Fenproporex;
  - 889 (E) Mazindol;
  - 890 (F) Mefenorex;
  - 891 (G) Modafinil;
  - 892 (H) Pemoline, including organometallic complexes and chelates thereof;
  - 893 (I) Phentermine;
  - 894 (J) Pipradrol;
  - 895 (K) Sibutramine; and
  - 896 (L) SPA ((-)-1-dimethylamino-1,2-diphenylethane).
- 897 (v) Unless specifically excepted or unless listed in another schedule, any material,  
898 compound, mixture, or preparation which contains any quantity of  
899 dextropropoxyphene (alpha-(+)-4-dimethylamino-1,  
900 2-diphenyl-3-methyl-2-propionoxybutane), including its salts.
- 901 (vi) A drug product or preparation that contains any component of marijuana and is  
902 approved by the United States Food and Drug Administration and scheduled by  
903 the Drug Enforcement Administration in Schedule IV of the federal Controlled  
904 Substances Act, Title II, P.L. 91-513.
- 905 (e) Schedule V:
- 906 (i) Any compound, mixture, or preparation containing any of the following limited  
907 quantities of narcotic drugs, or their salts calculated as the free anhydrous base or  
908 alkaloid, which includes one or more non-narcotic active medicinal ingredients in  
909 sufficient proportion to confer upon the compound, mixture, or preparation  
910 valuable medicinal qualities other than those possessed by the narcotic drug alone:
    - 911 (A) not more than 200 milligrams of codeine per 100 milliliters or per 100 grams;
    - 912 (B) not more than 100 milligrams of dihydrocodeine per 100 milliliters or per 100  
913 grams;

(C) not more than 100 milligrams of ethylmorphine per 100 milliliters or per 100 grams;

(D) not more than 2.5 milligrams of diphenoxylate and not less than 25 micrograms of atropine sulfate per dosage unit;

(E) not more than 100 milligrams of opium per 100 milliliters or per 100 grams;

(F) not more than 0.5 milligram of difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit; and

(G) unless specifically exempted or excluded or unless listed in another schedule, any material, compound, mixture, or preparation which contains Pyrovalerone having a stimulant effect on the central nervous system, including its salts, isomers, and salts of isomers.

(ii) A drug product or preparation that contains any component of marijuana, including cannabidiol, and is approved by the United States Food and Drug Administration and scheduled by the Drug Enforcement Administration in Schedule V of the federal Controlled Substances Act, Title II, P.L. 91-513.

(iii) Gabapentin.

#### Section 4. **Effective Date.**

This bill takes effect:

(1) except as provided in Subsection (2), May 6, 2026; or

(2) if approved by two-thirds of all members elected to each house:

(a) upon approval by the governor;

(b) without the governor's signature, the day following the constitutional time limit of Utah Constitution, Article VII, Section 8; or

(c) in the case of a veto, the date of veto override.